Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III studyGROEN, H. J. M; VAN DER LEEST, A. H. W; VAN PUTTEN, J. W. G et al.Annals of oncology. 2004, Vol 15, Num 3, pp 427-432, issn 0923-7534, 6 p.Article

Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatmentFOKKEMA, E; DE VRIES, E. G. E; GROEN, H. J. M et al.Virchows Archiv. 2003, Vol 442, Num 4, pp 349-355, issn 0945-6317, 7 p.Article

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours : a phase 1 and pharmacokinetic studyFOKKEMA, E; VERWEIJ, J; VAN OOSTEROM, A. T et al.British journal of cancer. 2000, Vol 82, Num 4, pp 767-771, issn 0007-0920Article

Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patientsFOKKEMA, E; DE VRIES, E. G. E; MEIJER, S et al.Cancer chemotherapy and pharmacology. 2000, Vol 45, Num 1, pp 89-92, issn 0344-5704Article

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide : A non-cross-resistant scheduleGROEN, H. J. M; FOKKEMA, E; BIESMA, B et al.Journal of clinical oncology. 1999, Vol 17, Num 3, pp 927-932, issn 0732-183XArticle

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancerFOKKEMA, E; GROEN, H. J. M; BAUER, J et al.Journal of clinical oncology. 1999, Vol 17, Num 12, pp 3822-3827, issn 0732-183XArticle

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancerSMIT, E. F; FOKKEMA, E; BIESMA, B et al.British journal of cancer. 1998, Vol 77, Num 2, pp 347-351, issn 0007-0920Article